HRP20110768T1 - Pirazolopirimidinonski inhibitor kinaze - Google Patents

Pirazolopirimidinonski inhibitor kinaze Download PDF

Info

Publication number
HRP20110768T1
HRP20110768T1 HR20110768T HRP20110768T HRP20110768T1 HR P20110768 T1 HRP20110768 T1 HR P20110768T1 HR 20110768 T HR20110768 T HR 20110768T HR P20110768 T HRP20110768 T HR P20110768T HR P20110768 T1 HRP20110768 T1 HR P20110768T1
Authority
HR
Croatia
Prior art keywords
compound
individual
pharmaceutically acceptable
active substance
acceptable salt
Prior art date
Application number
HR20110768T
Other languages
English (en)
Croatian (hr)
Inventor
F. Kluge Arthur
Original Assignee
Agennix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Ag filed Critical Agennix Ag
Publication of HRP20110768T1 publication Critical patent/HRP20110768T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20110768T 2007-05-29 2008-05-28 Pirazolopirimidinonski inhibitor kinaze HRP20110768T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93215507P 2007-05-29 2007-05-29
EP07113226A EP2019101A1 (en) 2007-07-26 2007-07-26 Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
PCT/EP2008/056569 WO2008145678A1 (en) 2007-05-29 2008-05-28 Pyrazolopyrimidinone kinase inhibitor

Publications (1)

Publication Number Publication Date
HRP20110768T1 true HRP20110768T1 (hr) 2011-11-30

Family

ID=38556321

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110768T HRP20110768T1 (hr) 2007-05-29 2008-05-28 Pirazolopirimidinonski inhibitor kinaze

Country Status (19)

Country Link
US (2) US8304418B2 (enExample)
EP (2) EP2019101A1 (enExample)
JP (1) JP2010528088A (enExample)
KR (1) KR20100040806A (enExample)
CN (1) CN101765600A (enExample)
AR (1) AR066737A1 (enExample)
AT (1) ATE522533T1 (enExample)
AU (1) AU2008257534A1 (enExample)
CA (1) CA2689090A1 (enExample)
DK (1) DK2170891T3 (enExample)
EA (1) EA200901536A1 (enExample)
ES (1) ES2370677T3 (enExample)
HR (1) HRP20110768T1 (enExample)
IL (1) IL202375A0 (enExample)
MX (1) MX2009012832A (enExample)
SI (1) SI2170891T1 (enExample)
TW (1) TW200906831A (enExample)
WO (1) WO2008145678A1 (enExample)
ZA (1) ZA200908943B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102428086B (zh) * 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
WO2015172713A1 (zh) * 2014-05-13 2015-11-19 广东东阳光药业有限公司 一种中间体的制备方法
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
EG18377A (en) * 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
RU2139731C1 (ru) * 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6559152B2 (en) * 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
ATE365749T1 (de) 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
IT1317975B1 (it) 2000-06-16 2003-07-21 Christian Pio Pedulla Presa multipla volante.
US20040248905A1 (en) * 2001-07-10 2004-12-09 Markwalder Jay A 6-Substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
PL369742A1 (en) * 2001-10-15 2005-05-02 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
JP5064795B2 (ja) * 2003-04-07 2012-10-31 アジェニックス ユーエスエー インク． サイクリン依存性キナーゼの阻害剤、組成物及びそれに関連する使用
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
BRPI0418095A (pt) 2003-12-23 2007-04-17 Gpc Biotech Inc inibidores de quinases dependentes de ciclina, composições e usos relacionados aos mesmos

Also Published As

Publication number Publication date
EP2019101A1 (en) 2009-01-28
IL202375A0 (en) 2010-06-30
US8304418B2 (en) 2012-11-06
US20130035349A1 (en) 2013-02-07
DK2170891T3 (da) 2011-12-12
CA2689090A1 (en) 2008-12-04
WO2008145678A1 (en) 2008-12-04
TW200906831A (en) 2009-02-16
AU2008257534A1 (en) 2008-12-04
ATE522533T1 (de) 2011-09-15
AR066737A1 (es) 2009-09-09
EA200901536A1 (ru) 2010-06-30
JP2010528088A (ja) 2010-08-19
MX2009012832A (es) 2010-05-17
KR20100040806A (ko) 2010-04-21
CN101765600A (zh) 2010-06-30
SI2170891T1 (sl) 2011-12-30
ZA200908943B (en) 2010-08-25
US20100160350A1 (en) 2010-06-24
EP2170891A1 (en) 2010-04-07
ES2370677T3 (es) 2011-12-21
EP2170891B1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
AU2015319831B2 (en) Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof
Hussain et al. Fruitful decade for antileishmanial compounds from 2002 to late 2011
US11918562B2 (en) Combination therapy using azabicyclo compound for cancer
JP6509386B2 (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
DK2580206T3 (en) PHARMACEUTICAL COMPOSITION, WHICH INCLUDES an amide derivative or a pharmaceutically acceptable salt thereof
KR20050075005A (ko) 암을 치료하는 방법 및 관련 방법
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
SK363392A3 (en) Stabilized pharmaceutical agent containing hgm-coa compound of inhibitor of reductase
TW202033191A (zh) 新穎藥物組成物及其用途
HRP20110768T1 (hr) Pirazolopirimidinonski inhibitor kinaze
RU2435587C2 (ru) Средство, потенцирующее радиационную терапию
US8580793B2 (en) Use of kinase inhibitor for the treatment of thymoma
JP6931067B2 (ja) Ｉｄｏの発現が関与する疾患の予防及び／又は治療剤
TW200914008A (en) Raf inhibitors for the treatment of thyroid cancer
EP3195867A1 (en) Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin e2, method of production thereof and use thereof
RU2821034C2 (ru) Химиотерапия рака с применением азабициклосоединения
HK40020714A (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
KR20230019590A (ko) 피롤로피리미딘아민 유도체를 유효성분으로 함유하는 항암 방사선 치료 민감제
AU2016227883A1 (en) 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments
CN121013721A (zh) 包含kras抑制剂和sph2抑制剂的组合疗法
SK171199A3 (en) Method for producing medicaments containing hmg-coa-reductase inhibitors
AU2019460715A1 (en) Cancer combination therapy using azabicyclic compound and polyadenosine-5'-diphosphate ribose polymerase inhibitor
KR20230019581A (ko) 피롤로피리미딘 유도체를 유효성분으로 함유하는 항암 방사선 치료 민감제
HK1130481B (en) Potentiator of radiation therapy